Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Eli Lilly has made the decision to discontinue manufacturing its migraine therapy Reyvow® (lasmiditan tablets), according to the Food and Drug Administration’s Drug Shortages tracker.
Approved in 2019, Reyvow is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. The decision to discontinue production was driven by business considerations rather than concerns about the product’s safety or effectiveness. Declining sales and increased market competition likely played a role in Lilly’s choice.
Additionally, Reyvow is classified as a Schedule V controlled substance, which may have limited its adoption. Side effects of the drug include dizziness and sedation that may cause significant driving impairment. In the product labeling, it is recommended that patients not engage in activities that require mental alertness, such as driving, for at least 8 hours after a dose of Reyvow. Individuals unable to follow this guidance were advised to avoid taking the medication.
A list of alternative migraine therapies can be found here.
This article originally appeared on MPR
References:
- US Food and Drug Administration. Lasmiditan succinate tablet. FDA Drug Shortages. Accessed November 5, 2025. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lasmiditan+Succinate+Tablet&st=d&tab=tabs-4&panels=0.
- Reyvow. Package insert. Eli Lilly; 2022. Accessed November 5, 2025. https://uspl.lilly.com/reyvow/reyvow.html#pi.
